Clinical and pharmacological aspects of induction-maintenance therapy in HIV-1 positive patients: the ADAM study

Authors	M.H.E. Reijers
Supervisors	J.M.A. Lange
Cosupervisors	R.M.W. Hoetelmans G.J. Weverling
Award date	28-09-2000
Number of pages	176
Organisations	Faculty of Medicine (AMC-UvA)
Document type	PhD thesis
Note	Research conducted at: Infectieziekten
Language	English
Downloads	Thesis Cover Titlepage Contents Chapter 1 Introduction. Chapter 2 Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Chapter 3 The ADAM study continued: maintenance therapy after 50 weeks of induction therapy. Chapter 4 The steady-state pharmacokinetics of nelfinavir (Viracept®) and saquinavir (Invirase®) during a quadruple antiretroviral drug regimen in HIV-1-infected individuals. Chapter 5 The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. Chapter 6 Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating the ADAM study. Chapter 7 Quality of life in maintenance- vs prolonged induction therapy for HIV. Chapter 8 Concentrations of stavudine, lamivudine, nelfinavir, and saquinavir in plasma, cerebrospinal fluid, and seminal plasma of HIV-1-infected individuals. Chapter 9 Stavudine concentrations in the plasma and cerebrospinal fluid: A possible interaction with ritonavir and/or indinavir? Chapter 10 General discussion. Summary Samenvatting Dankwoord Stellingen Cover
Permalink to this page

Back

UvA-DARE